IRLAB Therapeutics: IRL757 starts Ph 1b - ABG

Ph 1b in PD-apathy starts in H2'25
Safety and early efficacy the main goals
Comes with USD 4.5m cash injection from MSRD


Ph 1b in PD-apathy with MSRD

Today IRLAB Therapeutics announced the initiation of a Ph 1b study with the apathy candidate IRL757. The first patient in (FPI) is planned for H2'25 and IRLAB's collaboration partner MSRD will finance the startup cost through an initial payment of USD 4.5m to be booked still in Q1. The decision builds on the collaboration agreement signed with MSRD in May'24.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2025/3/irlab-therapeutics---irl757-starts-ph-1b/